Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry —Defining the “Goods” at Stake
AbstractCancer is a major burden on populations and health systems internationally. The development of innovative cancer medicines is seen as a significant part of the solution. These new cancer medicines are, however, expensive, leading to limited or delayed access and disagreements among stakeholders about which medicines to fund. There is no obvious resolution to these disagreements, with stakeholders holding firmly to divergent positions. Access to cancer medicines was recently explored in Australia in a Senate Inquiry into theAvailability of New, Innovative, and Specialist Cancer Drugs in Australia. We analysed the resultant Senate Report to identify competing stakeholder values. Our analysis illustrates that there are four main “goods” prioritized by different stakeholders: 1) innovation, 2) compassion, 3) equity, and 4) sustainability. We observe that, with the exception of sustainability, all of these “goods” put pressure on payers to provide access to cancer medicines more quickly and based on less rigorous eval uation processes. We then explore the consequences of giving in to such pressure and suggest that deconstructing the implicit values in calls for “enhanced access” to cancer medicines is necessary so that more nuanced solutions to the challenge of providing access to these high cost medicines ca n be found.
Abstract ObjectivesTo evaluate predictors of long‐term survival for patients with chronic kidney disease primarily due to surgery (CKD‐S). Patients with CKD‐S have generally good survival that approximates patients who do not have CKD even after renal cancer surgery (RCS), yet there may be heterogeneity within this cohort. Patients and MethodsFrom 1997‐2008, 4,246 patients underwent RCS at our center. Median follow‐up was 9.4 years (IQR=7.3‐11.0). New baseline GFR was defined as highest GFR between nadir and 6 weeks after surgery. We retrospectively evaluated 3 cohorts: no‐CKD (new baseline GFR≥60ml/min/1....
Vicky Veness shared a photo of herself looking healthy that was taken just hours before she was diagnosed.
ConclusionsAlthough the addition of chemotherapy to adjuvant RT has been proven effective in randomized trials of patients with resected HNSCC with SM+ or ECE, it may be less efficacious in an elderly patient population treated outside of a controlled trial setting. Level of Evidence2c Laryngoscope, 2017
Nor I. A. Rahman, Nor A. Abdul Murad, Mohammad M. Mollah, Rahman Jamal, Roslan Harun
Emma C. Fields, William P. McGuire, Lilie Lin, Sarah M. Temkin
CONCLUSIONCISNET models demonstrate that the greatest mortality reduction is achieved with annual screening of women starting at age 40 years. Cancer 2017. © 2017 American Cancer Society.
Audrey Aussy, Olivier Boyer, Nad ège Cordel
Pek Siew Lim, Kum Kum Khanna, Sudha Rao
By definition, alternative medicine has not been shown to be effective or has been shown to be ineffective. Thus, alternative medicine is ineffective against cancer and can best be represented as either no treatment at all or potentially harmful treatment. It is thus not surprising that cancer patients who choose alternative medicine have a higher risk of dying from their cancer. A new study confirms this conclusion yet again.
Despite the apparent technological advantages of SPECT/CT, PET/CT, and PET/MRI,...Read more on AuntMinnie.comRelated Reading: ASTRO updates guidelines on painful bone metastases PET/CT CAD finds common spinal metastases PET/MRI detects distant metastasis of breast cancer DC docs use MR-HIFU to treat bone tumor FDG-PET/MRI shows advantages with malignant bone lesions